Equities analysts expect Insys Therapeutics (NASDAQ:INSY) to post $26.09 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Insys Therapeutics’ earnings. The lowest sales estimate is $25.00 million and the highest is $27.17 million. Insys Therapeutics reported sales of $35.96 million in the same quarter last year, which indicates a negative year-over-year growth rate of 27.4%. The company is expected to announce its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Insys Therapeutics will report full-year sales of $118.52 million for the current financial year, with estimates ranging from $108.40 million to $127.00 million. For the next year, analysts forecast that the company will post sales of $160.44 million per share, with estimates ranging from $157.00 million to $163.88 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insys Therapeutics.
Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.47). The firm had revenue of $31.49 million for the quarter, compared to analyst estimates of $34.00 million. Insys Therapeutics had a negative net margin of 162.07% and a negative return on equity of 24.02%. Insys Therapeutics’s revenue for the quarter was down 42.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.03 earnings per share.
Large investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC bought a new stake in Insys Therapeutics during the 3rd quarter worth approximately $135,000. Stone Ridge Asset Management LLC bought a new position in shares of Insys Therapeutics during the 4th quarter worth approximately $137,000. Virtu Financial LLC grew its stake in shares of Insys Therapeutics by 96.8% during the 4th quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock worth $193,000 after acquiring an additional 9,866 shares in the last quarter. Raymond James & Associates grew its stake in shares of Insys Therapeutics by 93.5% during the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock worth $298,000 after acquiring an additional 14,982 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Insys Therapeutics by 50.1% during the 3rd quarter. Wells Fargo & Company MN now owns 41,516 shares of the specialty pharmaceutical company’s stock worth $368,000 after acquiring an additional 13,849 shares in the last quarter. Institutional investors and hedge funds own 24.05% of the company’s stock.
NASDAQ:INSY traded down $0.17 during mid-day trading on Monday, hitting $6.92. The stock had a trading volume of 534,119 shares, compared to its average volume of 1,245,523. The company has a market cap of $498.95, a PE ratio of -14.16 and a beta of 1.13. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.
ILLEGAL ACTIVITY WARNING: “Insys Therapeutics (INSY) Expected to Announce Quarterly Sales of $26.09 Million” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://weekherald.com/2018/04/26/insys-therapeutics-insy-expected-to-announce-quarterly-sales-of-26-09-million.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.